Introduction
Global Blood Therapeutics (GBT) recently reported top-line results of its Phase III HOPE U.S. clinical study of Voxelotor in patients with Sickle Cell Disease or SCD. Following the positive phase III HOPE study clinical trial results on June 14, 2019, the stock price surged over 10% over the next week. We believe that the company is well-positioned to receive the FDA approval for Voxelotor for the treatment of SCD with a potential annual peak revenue of over $2 billion by the patent expiration in 2032. The efficacy and safety profile of 1500mg